{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:33:00Z","timestamp":1792503180450,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00692-z","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T17:01:48Z","timestamp":1735491708000},"page":"5-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Scherlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Club for Innovative Immunotherapies in Immune-Mediated Inflammatory Diseases (C3I)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"692_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/art.41812","volume":"73","author":"C Orvain","year":"2021","unstructured":"Orvain C, Boulch M, Bousso P, Allanore Y, Avouac J. Is There a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73:1954\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard-2024-225727","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett G, Nagy G, Kronke G, Mielenz D. B-cell depletion in autoimmune diseases. Ann Rheum Dis. 2024;83:1409\u201320.","journal-title":"Ann Rheum Dis"},{"key":"692_CR3","first-page":"1409","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett G, Muller F, Taubmann J, Mackensen A, Wang W, Furie RA, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;83:1409\u201320.","journal-title":"Nat Rev Rheumatol"},{"key":"692_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S, et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med. 2024;390:687\u2013700.","journal-title":"N Engl J Med"},{"key":"692_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306.","journal-title":"Blood"},{"key":"692_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"692_CR7","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","volume":"192","author":"LG Barnett","year":"2014","unstructured":"Barnett LG, Simkins HM, Barnett BE, Korn LL, Johnson AL, Wherry EJ, et al. B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J Immunol. 2014;192:3607\u201317.","journal-title":"J Immunol"},{"key":"692_CR8","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","volume":"178","author":"M Duddy","year":"2007","unstructured":"Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007;178:6092\u20139.","journal-title":"J Immunol"},{"key":"692_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","volume":"23","author":"VR Moulton","year":"2017","unstructured":"Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23:615\u201335.","journal-title":"Trends Mol Med"},{"key":"692_CR10","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccines Immunother. 2018;14:2820\u201341.","journal-title":"Hum Vaccines Immunother"},{"key":"692_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215\u201326.","journal-title":"Arthritis Rheum"},{"key":"692_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/annrheumdis-2018-214833","volume":"78","author":"M Scherlinger","year":"2019","unstructured":"Scherlinger M, Carcaud C, Truchetet ME, Barnetche T, Duffau P, Couzi L, et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Ann Rheum Dis. 2019;78:1007\u201310.","journal-title":"Ann Rheum Dis"},{"key":"692_CR13","doi-asserted-by":"publisher","first-page":"E489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizak A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3:E489\u201397.","journal-title":"Lancet Rheumatol."},{"key":"692_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20:179\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"692_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"FH Du","year":"2017","unstructured":"Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8:12.","journal-title":"Auto Immun Highlights."},{"key":"692_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","volume":"48","author":"G Boleto","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, et al. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum. 2018;48:149\u201354.","journal-title":"Semin Arthritis Rheum"},{"key":"692_CR17","doi-asserted-by":"publisher","first-page":"SI163","DOI":"10.1093\/rheumatology\/keab815","volume":"61","author":"J Avouac","year":"2022","unstructured":"Avouac J, Miceli-Richard C, Combier A, Steelandt A, Fogel O, Mariaggi AA, et al. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients. Rheumatology (Oxford). 2022;61:SI163\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"692_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","volume":"5","author":"JY Wang","year":"2023","unstructured":"Wang JY, Wang L. CAR-T cell therapy: where are we now, and where are we heading? Blood Sci. 2023;5:237\u201348.","journal-title":"Blood Sci."},{"key":"692_CR19","doi-asserted-by":"publisher","first-page":"e002907","DOI":"10.1136\/rmdopen-2022-002907","volume":"9","author":"U Blache","year":"2023","unstructured":"Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD Open. 2023;9:e002907.","journal-title":"RMD Open"},{"key":"692_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200080","volume":"10","author":"S Gupta","year":"2023","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA, et al. CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200080.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"692_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396.","journal-title":"Nat Rev Immunol"},{"key":"692_CR22","doi-asserted-by":"publisher","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","volume":"12","author":"JH Frenking","year":"2024","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2024;12:e009220.","journal-title":"J Immunother Cancer"},{"key":"692_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","volume":"36","author":"A Gajra","year":"2022","unstructured":"Gajra A, Zalenski A, Sannareddy A, Jeune-Smith Y, Kapinos K, Kansagra A. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice. Pharm Med. 2022;36:163\u201371.","journal-title":"Pharm Med."},{"key":"692_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","volume":"27","author":"J Meir","year":"2021","unstructured":"Meir J, Abid MA, Abid MB. State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplant Cell Ther. 2021;27:973\u201387.","journal-title":"Transplant Cell Ther."},{"key":"692_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"692_CR26","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"692_CR27","unstructured":"Cabaletta bio reports second quarter 2024 financial results and provides business update. https:\/\/www.cabalettabio.com\/investors\/news-events\/press-releases\/detail\/114\/cabaletta-bio-reports-second-quarter-2024-financial-results. Accessed 11 Nov 2024."},{"key":"692_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933468","volume":"13","author":"B Thoreau","year":"2022","unstructured":"Thoreau B, Chaigne B, Mouthon L. Role of B-cell in the pathogenesis of systemic sclerosis. Front Immunol. 2022;13: 933468.","journal-title":"Front Immunol"},{"key":"692_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78:979\u201387.","journal-title":"Ann Rheum Dis"},{"key":"692_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/ard-2023-225174","volume":"83","author":"W Merkt","year":"2024","unstructured":"Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Rohrich M, et al. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024;83:543\u20136.","journal-title":"Ann Rheum Dis"},{"key":"692_CR31","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329:2154\u201362.","journal-title":"JAMA"},{"key":"692_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/art.42677","volume":"76","author":"J Avouac","year":"2024","unstructured":"Avouac J, Cauvet A, Orvain C, Boulch M, Tilotta F, Tu L, et al. Effects of B cell depletion by CD19-targeted chimeric antigen receptor T cells in a murine model of systemic sclerosis. Arthritis Rheumatol. 2024;76:268\u201378.","journal-title":"Arthritis Rheumatol"},{"issue":"4890\u20134904","key":"692_CR33","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(4890\u20134904): e4899.","journal-title":"Cell"},{"key":"692_CR34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ard-2023-224848","volume":"83","author":"C Bracaglia","year":"2024","unstructured":"Bracaglia C, Merli P, Moran Alvarez P, Del Bufalo F, Messia V, Nicolai R, et al. Anti-CD19 car T cell therapy for refractory childhood-onset systemic lupus erythematosus. Ann Rheum Dis. 2024;83:12.","journal-title":"Ann Rheum Dis"},{"key":"692_CR35","first-page":"1","volume":"83","author":"R Nicolai","year":"2024","unstructured":"Nicolai R, Merli P, Moran Alvarez P, Del Bufalo F, Bracaglia C, Marasco E, et al. CD19-targeting CAR T cell therapy in a boy with refractory juvenile dermatomyositis. Ann Rheum Dis. 2024;83:1.","journal-title":"Ann Rheum Dis"},{"issue":"1809\u20131821","key":"692_CR36","volume":"13","author":"M Mingueneau","year":"2016","unstructured":"Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren\u2019s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;13(1809\u20131821): e1812.","journal-title":"J Allergy Clin Immunol"},{"key":"692_CR37","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83:1304\u201314.","journal-title":"Ann Rheum Dis"},{"key":"692_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8:5.","journal-title":"Signal Transduct Target Ther"},{"key":"692_CR39","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.18632\/oncotarget.26792","volume":"1","author":"C Sun","year":"2019","unstructured":"Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget. 2019;1:2369\u201383.","journal-title":"Oncotarget"},{"key":"692_CR40","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023;29:2041\u20137.","journal-title":"Nat Med"},{"key":"692_CR41","doi-asserted-by":"publisher","first-page":"e003464","DOI":"10.1136\/rmdopen-2023-003464","volume":"9","author":"G Nocturne","year":"2023","unstructured":"Nocturne G, Marmontel O, di Filippo M, Chretien P, Krzysiek R, Lifermann F, et al. Efficacy of daratumumab in refractory primary Sjogren disease. RMD Open. 2023;9:e003464.","journal-title":"RMD Open"},{"key":"692_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","volume":"20","author":"S Cole","year":"2018","unstructured":"Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2018;20:85.","journal-title":"Arthritis Res Ther"},{"key":"692_CR43","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023;41:1229\u201338.","journal-title":"Nat Biotechnol"},{"key":"692_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179\u201384.","journal-title":"Science"},{"key":"692_CR45","unstructured":"Mog B, Shaw E, Hwang M, Pearlman A, DiNapoli S, Paul S. Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells. Arthritis Rheumatol. 2022;74."},{"key":"692_CR46","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, Camisa B, Toma C, Norata R, et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat Commun. 2024;15:2542.","journal-title":"Nat Commun"},{"key":"692_CR47","first-page":"555","volume":"28","author":"P Morfino","year":"2023","unstructured":"Morfino P, Aimo A, Castiglione V, Galvez-Monton C, Emdin M, Bayes-Genis A. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. Heart Fail Rev. 2023;28:555\u201369.","journal-title":"Heart Fail Rev"},{"key":"692_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200859","volume":"32","author":"D Li","year":"2024","unstructured":"Li D, Wang W. Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells. Mol Ther Oncol. 2024;32: 200859.","journal-title":"Mol Ther Oncol."},{"key":"692_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152479","volume":"67","author":"R Ohno","year":"2024","unstructured":"Ohno R, Nakamura A. Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies\u2014evidence, safety, and future directions. Semin Arthritis Rheum. 2024;67: 152479.","journal-title":"Semin Arthritis Rheum"},{"key":"692_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29:440\u20138.","journal-title":"Transplant Cell Ther."},{"key":"692_CR51","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson MJ, Barba P, Jager U, Shah NN, Blaise D, Briones J, et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 2023;13:1982\u201397.","journal-title":"Cancer Discov"},{"key":"692_CR52","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138:2469\u201384.","journal-title":"Blood"},{"key":"692_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"692_CR54","unstructured":"FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell Immunotherapies. https:\/\/www.fdagov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed 11 Nov 2024."},{"key":"692_CR55","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390:2047\u201360.","journal-title":"N Engl J Med"},{"key":"692_CR56","doi-asserted-by":"publisher","first-page":"60 e61","DOI":"10.1016\/j.jtct.2022.09.022","volume":"29","author":"NH Fowler","year":"2023","unstructured":"Fowler NH, Dickinson M, Ghosh M, Chen AI, Andreadis C, Tiwari R, et al. Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study. Transplant Cell Ther. 2023;29:60 e61-60 e64.","journal-title":"Transplant Cell Ther."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00692-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00692-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00692-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T22:03:03Z","timestamp":1737496983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00692-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00692-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]},"assertion":[{"value":"13 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Innate Pharma, Nordic Pharma, Novartis, Sandoz. JA received honoraria from Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD; and research grants from Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos, Nordic Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of funding"}},{"value":"JA conceived and planned the review; conducted the literature search and data synthesis; wrote the majority of the manuscript and coordinated final revisions. MS contributed to the literature search; provided suggestions and improvements to the manuscript structure; reviewed and validated scientific content; participated in final revisions for approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials (data transparency):"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}}]}}